By Ingfei Chen

A Prostate Cancer Prevention Pill Looks Safer

Yet questions remain about finasteride's true long-term risks and benefits

By Ingfei Chen

It seemed a Faustian deal: In 2003, the $73 million Prostate Cancer Prevention Trial (PCPT) found that a pill called Proscar (finasteride) cut the incidence of prostate tumors—mainly the slow-growing, low-grade types—by almost 25 percent. But it also slightly boosted the incidence of the deadliest prostate cancers.

Last September, ...

To view the complete article, please log in. Your subscriber ID is located on your mailing label and begins with the letters CA.

Subscriber ID


ZIP Code